These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9232838)

  • 1. Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series).
    Orsini F; Pelizzoni F; Bellini B; Miglierini G
    Carbohydr Res; 1997 Jun; 301(3-4):95-109. PubMed ID: 9232838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds.
    Orsini F; Pelizzoni F; Verotta L; Aburjai T; Rogers CB
    J Nat Prod; 1997 Nov; 60(11):1082-7. PubMed ID: 9392877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of mustard derivatives of combretastatins.
    Coggiola B; Pagliai F; Allegrone G; Genazzani AA; Tron GC
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3551-4. PubMed ID: 15963722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to combretastatin D2.
    Cousin D; Mann J; Nieuwenhuyzen M; van den Berg H
    Org Biomol Chem; 2006 Jan; 4(1):54-62. PubMed ID: 16357997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents.
    Pirali T; Busacca S; Beltrami L; Imovilli D; Pagliai F; Miglio G; Massarotti A; Verotta L; Tron GC; Sorba G; Genazzani AA
    J Med Chem; 2006 Aug; 49(17):5372-6. PubMed ID: 16913727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic agents. 579. Synthesis and cancer cell growth evaluation of E-stilstatin 3: a resveratrol structural modification.
    Pettit GR; Melody N; Thornhill A; Knight JC; Groy TL; Herald CL
    J Nat Prod; 2009 Sep; 72(9):1637-42. PubMed ID: 19719153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of double bond substituted combretastatins.
    Hadfield JA; Gaukroger K; Hirst N; Weston AP; Lawrence NJ; McGown AT
    Eur J Med Chem; 2005 Jun; 40(6):529-41. PubMed ID: 15922837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antimicrotubule activity of combretatropone derivatives.
    Janik ME; Bane SL
    Bioorg Med Chem; 2002 Jun; 10(6):1895-903. PubMed ID: 11937347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
    Siles R; Ackley JF; Hadimani MB; Hall JJ; Mugabe BE; Guddneppanavar R; Monk KA; Chapuis JC; Pettit GR; Chaplin DJ; Edvardsen K; Trawick ML; Garner CM; Pinney KG
    J Nat Prod; 2008 Mar; 71(3):313-20. PubMed ID: 18303849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
    Cushman M; Nagarathnam D; Gopal D; He HM; Lin CM; Hamel E
    J Med Chem; 1992 Jun; 35(12):2293-306. PubMed ID: 1613753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical design of antimitotic agents based on combretastatins.
    Hsieh HP; Liou JP; Mahindroo N
    Curr Pharm Des; 2005; 11(13):1655-77. PubMed ID: 15892667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents.
    Monk KA; Siles R; Hadimani MB; Mugabe BE; Ackley JF; Studerus SW; Edvardsen K; Trawick ML; Garner CM; Rhodes MR; Pettit GR; Pinney KG
    Bioorg Med Chem; 2006 May; 14(9):3231-44. PubMed ID: 16442292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular design of potent tyrosinase inhibitors having the bibenzyl skeleton.
    Oozeki H; Tajima R; Nihei K
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5252-4. PubMed ID: 18782667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity studies of novel combretastatin and pterostilbene derivatives.
    Jakubowska J; Mikuła-Pietrasik J; Książek K; Krawczyk H
    Biomed Res Int; 2014; 2014():320895. PubMed ID: 25157353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activity of fluorinated combretastatin analogues.
    Alloatti D; Giannini G; Cabri W; Lustrati I; Marzi M; Ciacci A; Gallo G; Tinti MO; Marcellini M; Riccioni T; Guglielmi MB; Carminati P; Pisano C
    J Med Chem; 2008 May; 51(9):2708-21. PubMed ID: 18396857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4.
    Aleksandrzak K; McGown AT; Hadfield JA
    Anticancer Drugs; 1998 Jul; 9(6):545-50. PubMed ID: 9877243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioactive compounds from Combretum erythrophyllum.
    Schwikkard S; Zhou BN; Glass TE; Sharp JL; Mattern MR; Johnson RK; Kingston DG
    J Nat Prod; 2000 Apr; 63(4):457-60. PubMed ID: 10785413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
    Pettit GR; Grealish MP; Jung MK; Hamel E; Pettit RK; Chapuis JC; Schmidt JM
    J Med Chem; 2002 Jun; 45(12):2534-42. PubMed ID: 12036362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity.
    Hatanaka T; Fujita K; Ohsumi K; Nakagawa R; Fukuda Y; Nihei Y; Suga Y; Akiyama Y; Tsuji T
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3371-4. PubMed ID: 9873736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and pharmacological evaluation of glycosides of resveratrol, pterostilbene, and piceatannol.
    Shimoda K; Kubota N; Uesugi D; Hamada H; Tanigawa M; Hamada H
    Ann N Y Acad Sci; 2015 Aug; 1348(1):141-9. PubMed ID: 26250502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.